Theratechnologies Price/Sales
What is the Price/Sales of Theratechnologies?
The Price/Sales of Theratechnologies, Inc. is 1.14
What is the definition of Price/Sales?
Price to sales ratio is a company’s stock price compared to its revenues.
ttm (trailing twelve months)
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Price/Sales of companies in the Health Care sector on TSX compared to Theratechnologies
What does Theratechnologies do?
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Companies with price/sales similar to Theratechnologies
- Travel Expert (Asia) Enterprises has Price/Sales of 1.14
- Spok Inc has Price/Sales of 1.14
- ZF Steering Gear (India) has Price/Sales of 1.14
- Encompass Health Corp has Price/Sales of 1.14
- Eastman Chemical has Price/Sales of 1.14
- Zensar Technologies has Price/Sales of 1.14
- Theratechnologies has Price/Sales of 1.14
- Interpublic Of Cos has Price/Sales of 1.14
- Richards Packaging Income Fund has Price/Sales of 1.14
- Cavco Industries Inc has Price/Sales of 1.14
- Emperor Capital has Price/Sales of 1.14
- Mindteck (India) has Price/Sales of 1.14
- The South Indian Bank has Price/Sales of 1.14